FEED (ENvue Medical) Cyclically Adjusted Revenue per Share: $136.98 (As of Mar. 2026)


FEED ENvue Medical Inc FEED
34 GF Score
Price $0.52
GF Value $5.13
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is ENvue Medical Cyclically Adjusted Revenue per Share?

ENvue Medical FEED -8.77% 34 Cyclically Adjusted Revenue per Share is $136.98 as of Mar. 2026. GuruFocus rates FEED with a GF Score™ of 34/100 and a GF Value™ of $5.13 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

ENvue Medical's adjusted revenue per share for the three months ended in Mar. 2026 was $0.199. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $136.98 for the trailing ten years ended in Mar. 2026.

During the past 12 months, ENvue Medical's average Cyclically Adjusted Revenue Growth Rate was -4.40% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -3.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of ENvue Medical was -3.60% per year. The lowest was -3.60% per year. And the median was -3.60% per year.

As of today (2026-07-05), ENvue Medical's current stock price is $0.524. ENvue Medical's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was $136.98. ENvue Medical's Cyclically Adjusted PS Ratio of today is 0.00.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ENvue Medical was 6.34. The lowest was 0.01. And the median was 0.52.


ENvue Medical  (NAS:FEED) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

ENvue Medical's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.524/136.98
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of ENvue Medical was 6.34. The lowest was 0.01. And the median was 0.52.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


ENvue Medical Cyclically Adjusted Revenue per Share Related Terms


ENvue Medical Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for ENvue Medical's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ENvue Medical Cyclically Adjusted Revenue per Share Chart

ENvue Medical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 154.60 156.40 143.67 138.29

ENvue Medical Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 143.28 142.91 141.25 138.29 136.98

FEED vs BTCY, LUDG, AMIX: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, ENvue Medical's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ENvue Medical Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ENvue Medical's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where ENvue Medical's Cyclically Adjusted PS Ratio falls into.


FEED
34GF Score
ENvue Medical Inc FEED
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ENvue Medical Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ENvue Medical's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.199/330.2130*330.2130
=0.199

Current CPI (Mar. 2026) = 330.2130.

ENvue Medical Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 31.000 241.018 42.472
201609 30.500 241.428 41.716
201612 24.500 241.432 33.509
201703 26.000 243.801 35.215
201706 26.000 244.955 35.049
201709 32.500 246.819 43.481
201712 23.333 246.524 31.254
201803 25.667 249.554 33.963
201806 44.000 251.989 57.659
201809 18.000 252.439 23.546
201812 18.000 251.233 23.659
201903 26.333 254.202 34.207
201906 87.667 256.143 113.018
201909 33.667 256.759 43.299
201912 29.000 256.974 37.265
202003 38.000 258.115 48.614
202006 89.667 257.797 114.855
202009 37.500 260.280 47.576
202012 9.000 260.474 11.410
202103 9.364 264.877 11.674
202106 28.909 271.696 35.135
202109 41.583 274.310 50.057
202112 64.583 278.802 76.492
202203 20.923 287.504 24.031
202206 37.308 296.311 41.577
202209 7.462 296.808 8.302
202212 -7.846 296.797 -8.729
202303 23.600 301.836 25.819
202306 19.600 305.109 21.213
202309 28.625 307.789 30.710
202312 65.389 306.746 70.391
202403 36.840 312.332 38.949
202406 32.680 314.175 34.348
202409 15.040 315.301 15.751
202412 13.059 315.605 13.663
202503 16.270 319.799 16.800
202506 10.292 322.561 10.536
202509 0.841 324.800 0.855
202512 0.284 324.054 0.289
202603 0.199 330.213 0.199

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $136.98 mean?
ENvue Medical (FEED) has a Cyclically Adjusted Revenue per Share of $136.98 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ENvue Medical and its competitors.
Is ENvue Medical's Cyclically Adjusted Revenue per Share too high?
ENvue Medical's current Cyclically Adjusted Revenue per Share is $136.98. Overall, ENvue Medical has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ENvue Medical's Cyclically Adjusted Revenue per Share compare to BTCY and LUDG?
ENvue Medical's Cyclically Adjusted Revenue per Share of $136.98 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on ENvue Medical and its competitors. ENvue Medical's current Cyclically Adjusted Revenue per Share is $136.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ENvue Medical stock overvalued right now?
Based on GuruFocus' analysis, ENvue Medical (FEED) is currently considered Possible Value Trap. The stock's GF Value™ is $5.13, compared to a current price of $0.52 — trading 89.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $136.98. ENvue Medical's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For ENvue Medical (FEED), the current Cyclically Adjusted Revenue per Share is $136.98 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ENvue Medical (FEED) Overvalued in 2026?

Based on GuruFocus' analysis, ENvue Medical stock appears to be undervalued. The current stock price of $0.52 is trading 89.8% below its estimated GF Value™ of $5.13. GuruFocus considers ENvue Medical to be Possible Value Trap.

Key valuation signals for FEED:

  • Cyclically Adjusted Revenue per Share: $136.98
  • GF Value™: $5.13 vs. price of $0.52 (89.8% below fair value)
  • GF Score™: 34/100 with 4 warning signs

No single metric tells the full story. See the FEED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


ENvue Medical Business Description

Address 969 Pruitt Avenue, Tyler, TX, USA, 77569
ENvue Medical Inc develops medical devices for enhanced navigation in clinical procedures. The company provides personalized navigation technology to assist clinicians in placing feeding tubes safely and efficiently. Its ENvue system uses smart feeding tubes with sensors, body mapping, and continuous visual guidance to confirm accurate positioning and reduce complications like lung misplacement. The company conducted the business through two primary operating segments: NanoVibronix and ENvue. The firm generates the majority of its revenue from NanoVibronix, which derives revenues from selling its products directly to patients as well as through distributor agreements. ENvue derives revenues from selling its Systems and Nasoenteral tubes.
34GF Score

Get the complete analysis for FEED

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.52
Price
$5.13
GF Value